The mechanism behind this unexpected benefit of a JAK2 inhibitor was poorly understood until momelotinib was shown to down-regulate hepatic hepcidin production via antagonism of the type 1 activin receptor (ACVR1/ALK2) and ameliorate anemia in a rodent model of anemia of chronic disease.64 This evidence concerns the gene JAK2 and anemia.